Prajapati Mrugesh, Patel Jigar, Patel Hasmukh, Gandhi Hemang, Singh Guriqbal, Patel Pravin
Department of Cardiac Anesthesia, U.N. Mehta Institute of Cardiology and Research Center (Affiliated to B. J. Medical College), Ahmadabad, Gujarat, India.
Ann Pediatr Cardiol. 2022 Jul-Aug;15(4):358-363. doi: 10.4103/apc.apc_230_21. Epub 2023 Jan 6.
The aim of the study was to compare the effect of two different regimens of milrinone in pediatric patients with pulmonary artery hypertension (PAH) undergoing corrective procedure.
This randomized prospective study included 100 pediatric patients undergoing corrective cardiac surgeries. Group E: Milrinone was started as infusion 0.5 μg/kg/min without a loading dose after induction of anesthesia and continued as infusion 0.5-0.75 μg/kg/min in the pediatric cardiac surgical intensive care unit (PSICU). Group L: Milrinone was started as a loading dose 50 μg/kg over 10 min before weaning from cardiopulmonary bypass (CPB) followed by infusion 0.5-0.75 μg/kg/min in the PSICU. We compared heart rate, mean arterial blood pressure, central venous pressure, cardiac index (CI), mean pulmonary arterial pressure (MPAP), serum lactate level, urine output, vasoactive inotropic score, mechanical ventilation duration, and intensive care unit (ICU)- and hospital length of stay between the groups.
There was an increase in mean arterial blood pressure, CI, and urine output in Group E compared to Group L ( < 0.05). MPAP, serum lactate level, and requirement of inotropes and vasopressors were lower in Group E compared to Group L ( < 0.05). Mechanical ventilation duration, ICU, and hospital length of stay were shorter in Group E than Group L ( < 0.05).
Early use of milrinone in patients with PAH undergoing corrective cardiac surgeries improved CI and mean arterial pressure, decreased MPAP, improved urine output, decreased serum lactate level, and decreased requirement of inotropes and vasopressors after weaning from CPB compared to the milrinone bolus group.
本研究旨在比较两种不同米力农给药方案对接受矫正手术的小儿肺动脉高压(PAH)患者的影响。
这项随机前瞻性研究纳入了100例接受心脏矫正手术的小儿患者。E组:麻醉诱导后开始以0.5μg/kg/min的速度输注米力农,无负荷剂量,并在小儿心脏外科重症监护病房(PSICU)继续以0.5 - 0.75μg/kg/min的速度输注。L组:在体外循环(CPB)撤机前10分钟给予50μg/kg的米力农负荷剂量,随后在PSICU以0.5 - 0.75μg/kg/min的速度输注。我们比较了两组之间的心率、平均动脉血压、中心静脉压、心脏指数(CI)、平均肺动脉压(MPAP)、血清乳酸水平、尿量、血管活性肌力评分、机械通气时间以及重症监护病房(ICU)住院时间和住院总时长。
与L组相比,E组的平均动脉血压、CI和尿量增加(<0.05)。与L组相比,E组的MPAP、血清乳酸水平以及对正性肌力药物和血管升压药的需求较低(<0.05)。E组的机械通气时间、ICU住院时间和住院总时长均短于L组(<0.05)。
与米力农推注组相比,在接受心脏矫正手术的PAH患者中早期使用米力农可改善CI和平均动脉压,降低MPAP,增加尿量,降低血清乳酸水平,并减少CPB撤机后对正性肌力药物和血管升压药的需求。